New hope for tough esophageal cancer: SYS6010 trial launches
NCT ID NCT07417735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests a new drug called SYS6010 against standard chemotherapy in people with advanced esophageal cancer that has worsened after at least one prior treatment. About 436 participants will be randomly assigned to receive either SYS6010 or a standard chemo drug. The main goals are to see if SYS6010 can delay cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC/RECURRENT ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••